Mostrar el registro sencillo del ítem

dc.contributor.authorNoyce, Alastair
dc.contributor.authorBrandes Ciga, Sara
dc.contributor.authorDurán Ogalla, Raquel 
dc.date.accessioned2019-11-15T12:46:36Z
dc.date.available2019-11-15T12:46:36Z
dc.date.issued2019
dc.identifier.citationNoyce, A., Ciga, S. B., Kim, J., Heilbron, K., Hemani, G., Xue, A., ... & Blauwendraat, C. (2019). The Parkinsons Disease Mendelian Randomization Research Portal. BioRxiv, 604033.es_ES
dc.identifier.urihttp://hdl.handle.net/10481/57927
dc.description.abstractMendelian randomization is a method for exploring observational associations to find evidence of causality. To apply Mendelian randomization between risk factors/phenotypic traits (exposures) and PD in a large, unbiased manner, and to create a public resource for research. We observed evidence for causal associations between 12 exposures and risk of PD. Of these, nine were effects related to increasing adiposity and decreasing risk of PD. The remaining top three exposures that affected PD risk were tea drinking, time spent watching television, and forced vital capacity, but these may have been biased and were less convincing. Other exposures at nominal statistical significance included inverse effects of smoking and alcohol. We present a new platform which offers Mendelian randomization analyses for a total of 5,839 genome-wide association studies versus the largest PD genome-wide association studies available (https://pdgenetics.shinyapps.io/MRportal/). Alongside, we report further evidence to support a causal role for adiposity on lowering the risk of PD. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.es_ES
dc.description.sponsorshipAJN reports grants from Parkinson’s UK, Barts Charity, Leonard Wolfson Experimental Neurology Centre, UCL Movement Disorders Centre and the Virginia Kieley Benefaction; honoraria or consultancy fees from Britannia, Global Kinetics Corporation, Profile Pharmaceuticals, Guide point, Biogen and Roche. KH and DAH are employees of 23andMe and hold stock or stock options in 23andMe. DAL reports grants from the Medical Research Council, numerous charitable funders,Medtronic and Roche. ZG-O reports consultancy fees from Inceptions Sciences,Idorsia, Denali, Lysosomal Therapeutics inc. HM reports reports consultancy from Biogen, UCB, Abbvie, Denali, Biohaven; lecture fees/honoraria from Biogen, UCB,C4X Discovery, GE-Healthcare, Welcome Trust, Movement Disorders Society; Research Grants from Parkinson’s UK, Cure Parkinson’s Trust, PSP Association, CBD Solutions, Drake Foundation, Medical Research Council. Dr Morris is a co-applicanton a patent application related to C9ORF72 (PCT/GB2012/052140).es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectMendelian randomizationes_ES
dc.subjectParkinson´s diseasees_ES
dc.subjectPublic resourcees_ES
dc.subjectRisk factores_ES
dc.titleThe Parkinson’s Disease Mendelian Randomization Research Portales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1002/mds.27873


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España